Market Overview

UPDATE: Jefferies Raises PT on Pfizer on Attractive Valuation

Related PFE
#PreMarket Movers From December 18, 2014: Rite Aid, Oracle, GoPro And More
Opko Health Inks Pfizer License Pact
Divided Government Won't Halt Street's Run (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), and raised the price target from $31.00 to $33.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Pfizer closed on Tuesday at $29.11.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2014Deutsche BankMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional